3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool

What's Going On With Novavax Stock On Friday?

Novavax stock surged 13.16% on Friday, tracking gains in Moderna following the publication of Phase 3 results for Moderna's mRNA-based seasonal flu vaccine in the New England Journal of Medicine. The article also notes Moderna's early-stage hantavirus vaccine research collaboration with the U.S. Army and Korea University. Novavax reported Q1 2025 sales of $139.51 million, beating estimates, though the company posted a net loss of $9 million compared to prior year income.

05/08/2026, 2:18 PM • Benzinga

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?

Novavax shares surged 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology, worth $30M upfront plus up to $500M in milestones. However, the analyst recommends staying away from the stock due to uncertain core business fundamentals, inconsistent revenue from its coronavirus vaccine franchise, pipeline risks including a clinical hold setback, and significant competition in vaccine development.

01/29/2026, 8:30 AM • The Motley Fool

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio surged 17.39% on January 20, 2026, following FDA end-of-phase discussions that outlined a resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. The stock has more than doubled in five days, driven by triple-digit revenue growth and expanding indications for its primary therapy, though investors should expect continued volatility.

01/26/2026, 5:02 PM • The Motley Fool

Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'

Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs.

09/26/2025, 12:08 AM • Benzinga

FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects

The FDA is seeking to lift privacy rules on COVID-19 vaccine data for pregnant women to reveal potential side effects, amid ongoing debates about vaccine safety and transparency led by health officials like FDA Commissioner Marty Makary.

09/10/2025, 1:21 PM • Benzinga

CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency

A gunman attacked CDC headquarters in Atlanta, allegedly motivated by anti-vaccine beliefs. Former CDC employees blame Robert F. Kennedy Jr.'s hostile rhetoric, and the NIH chief suggests mRNA vaccine platforms are losing public trust.

08/12/2025, 1:41 PM • Benzinga

Moderna's mRNA Flu Vaccine Outperforms Standard Shots

Moderna reported positive Phase 3 trial results for its mRNA-1010 flu vaccine, showing 26.6% higher efficacy compared to standard flu shots in adults over 50, with mild adverse reactions and strong performance across different influenza strains.

06/30/2025, 9:51 AM • Benzinga

Vaccine Adjuvants Market to Reach USD 5.43 Billion by 2032 Due to Increasing Demand for Enhanced Vaccine Efficacy and Global Immunization Programs – SNS Insider

The global vaccine adjuvants market is projected to grow from USD 3.83 billion in 2024 to USD 5.43 billion by 2032, with a 4.47% CAGR, driven by increasing vaccine efficacy demands and global immunization programs.

06/29/2025, 2:08 PM • GlobeNewswire